Recent research has shown that cancer cells have a much different ? and more complex ? metabolism than normal cells. Now, scientists at The University of Texas at Dallas have found that exploiting these differences might provide a new strategy to combat lung cancer.
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.
A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tumors, according findings to be presented by Fox Chase Cancer Center researchers at the AACR Annual Meeting 2013 on Tuesday, April 9.
Researchers at Moffitt Cancer Center have found a potential targeted therapy for patients with tobacco-associated non-small cell lung cancer. It is based on the newly identified oncogene IKBKE, which helps regulate immune response.
A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone in treating patients with the most common genetic subtype of lung cancer.
More effective treatments for one of the deadliest forms of cancer are one step closer thanks to groundbreaking research from an international collaborative study.
Scientists from the Universities of Sheffield and Cologne have identified the dependencies of multiple Small Cell Lung Cancer (SCLC) types ? paving the way for clinical trials of new targeted treatments which could revolutionise the current approach.
Researchers develop blood test that accurately detects early stages of lung, breast cancer in humans
Researchers at Kansas State University have developed a simple blood test that can accurately detect the beginning stages of cancer.
In less than an hour, the test can detect breast cancer and non-small cell lung cancer — the most common type of lung cancer — before symptoms like coughing and weight loss start. The researchers anticipate testing for the early stages of pancreatic cancer shortly.
A new research report published online in the FASEB Journal reveals a connection among sugar, cancer, and dependence on breathing machines–microRNA-320a. In the report, Stanford scientists show that the molecule microRNA-320a is responsible for helping control glycolysis. Glycolysis is the process of converting sugar into energy, which fuels the growth of some cancers, and contributes to the wasting of unused muscles such as the diaphragm when people are using ventilators. Identifying ways to use microRNA-320a to starve tumors and keep unused muscles strong would represent a significant therapeutic leap for numerous diseases and health conditions.
An antibody that helps a person’s own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center.
A team of researchers led by Dr. Goutham Narla at Case Western Reserve University School of Medicine in collaboration with scientists at Mount Sinai School of Medicine in New York, have discovered a previously unrecognized signaling network disrupted in lung cancer that can be turned back on by a novel combination of two previously approved FDA drugs. The drug combination targets a pathway to treat advanced/late stage lung cancer. The work highlights how understanding the basic mechanisms regulating cancer development and progression can lead to new uses for existing FDA approved drugs in the treatment of cancer.